Rye Brook Capital’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.07M | Buy |
24,300
+2,800
| +13% | +$354K | 3.21% | 10 |
|
|
2025
Q1 | $2.75M | Buy |
21,500
+200
| +0.9% | +$25.6K | 3.45% | 11 |
|
|
2024
Q4 | $2.82M | Buy |
+21,300
| New | +$2.82M | 3.38% | 10 |
|
|
2024
Q3 | – | Sell |
-19,300
| Closed | -$2.65M | – | 22 |
|
|
2024
Q2 | $2.65M | Sell |
19,300
-21,100
| -52% | -$2.9M | 3.48% | 12 |
|
|
2024
Q1 | $5.54M | Buy |
40,400
+400
| +1% | +$54.9K | 3.25% | 12 |
|
|
2023
Q4 | $5.43M | Sell |
40,000
-900
| -2% | -$122K | 2.78% | 12 |
|
|
2023
Q3 | $5M | Buy |
40,900
+100
| +0.2% | +$12.2K | 3.56% | 9 |
|
|
2023
Q2 | $5.18M | Buy |
40,800
+700
| +2% | +$88.9K | 2.45% | 6 |
|
|
2023
Q1 | $5.18M | Buy |
40,100
+50
| +0.1% | +$6.46K | 3.17% | 8 |
|
|
2022
Q4 | $5.26M | Sell |
40,050
-200
| -0.5% | -$26.3K | 3.41% | 7 |
|
|
2022
Q3 | $4.71M | Sell |
40,250
-56,090
| -58% | -$6.56M | 3.44% | 7 |
|
|
2022
Q2 | $11.3M | Buy |
96,340
+1,300
| +1% | +$153K | 6.9% | 5 |
|
|
2022
Q1 | $12.4M | Buy |
95,040
+100
| +0.1% | +$13K | 4.89% | 4 |
|
|
2021
Q4 | $14.5M | Buy |
94,940
+27,400
| +41% | +$4.18M | 3.71% | 4 |
|
|
2021
Q3 | $10.9M | Buy |
67,540
+3,600
| +6% | +$582K | 7.68% | 3 |
|
|
2021
Q2 | $10.5M | Buy |
63,940
+15,000
| +31% | +$2.45M | 7.4% | 3 |
|
|
2021
Q1 | $7.37M | Buy |
48,940
+9,100
| +23% | +$1.37M | 5.37% | 9 |
|
|
2020
Q4 | $6.04M | Buy |
+39,840
| New | +$6.04M | 5.26% | 8 |
|